Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CLYM vs SGMO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CLYM Captures Overall Composite Edge (41.9 SELL vs 52.0 HOLD), While SGMO Leads 4–1 on Growth & Valuation Pillars

CLYM Overall Winner 6-Pillar Tally: CLYM 1 – 4 SGMO (1 Tie) Matrix Metrics: CLYM 5 – 4 SGMO

As of Nov 16, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Sangamo Therapeutics, Inc. (SGMO) on higher Unified Composite conviction (41.9/100 SELL vs. 52.0/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while SGMO wins 4–1 across the 6-pillar growth and valuation breakdown. CLYM trades at $9.99 (N/M Forward P/E, 0.0% operating margin) versus SGMO at $0.18 (0.4x Forward P/E, -175.5% operating margin).

  • Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. CLYM 41.9/100 SELL), CLYM captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY).
  • Technical & Structure Timing Caution: CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CLYM vs SGMO
CLYM NASDAQ Head-to-Head Winner
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.99
-3.52% 1D
Market Cap $638.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.51β · 114% Vol
Unified Composite Score
41.9 / 100 SELL
Tech 38.0 Fund 42.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.5 · SMA20: $10.28 · SMA50: $11.47
SGMO NASDAQ
Sangamo Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.18
+31.56% 1D
Market Cap $55.9M
TTM Revenue $40M
Forward P/E 0.4x
Beta / 30D Vol 1.49β · 206% Vol
Unified Composite Score
52.0 / 100 HOLD
Tech 25.0 Fund 46.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.4%), weak momentum, RSI 38
RSI-14: 38.4 · SMA20: $0.23 · SMA50: $0.31

6-Pillar Scorecard Institutional Category Breakdown (CLYM 1 – 4 SGMO)

Columns: Metric · CLYM · SGMO
1. Valuation Multiples SGMO
Forward P/E N/M 0.4x
Trailing P/E N/M 0.4x
PEG Ratio N/M N/M
EV / Revenue N/M 1.2x
2. Growth & Scale SGMO
Revenue Growth (YoY) +0.0% +88.4%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $40M
Market Cap $638.5M $55.9M
3. Profitability & Quality CLYM
Gross Margin N/A N/A
Operating Margin 0.0% -175.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -29.3% -2891.8%
4. Balance Sheet & Cash Flow SGMO
Cash Generation (TTM) N/A -$90M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.95 Book/Sh · -29.3% ROE $8.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 144.2% (71st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CLYM (5) vs SGMO (4)
Institutional Metric CLYM SGMO Criterion Row Edge
Market Capitalization
Scale
$638.5M $55.9M Larger Scale CLYM
Trailing P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Forward P/E Ratio
Valuation
N/M 0.4x Lower Multiple SGMO
Revenue Growth (YoY)
Growth
+0.0% +88.4% Higher Growth SGMO
Operating Margin (TTM)
Profitability
0.0% -175.5% Higher Margin CLYM
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-29.3% -2891.8% Higher ROE CLYM
52-Week Range Position
Momentum
50% ($2–$18) 9% ($0–$1) Stronger Trend CLYM
Beta / 30D Volatility
Risk Regime
1.51β · 114% Vol 1.49β · 206% Vol Lower Realized Risk CLYM
Unified Institutional Score
Composite Signal
41.9 / 100 (SELL) 52.0 / 100 (HOLD) Higher Composite SGMO
Trailing 12M Revenue (USD)
Operating Scale
N/A $40M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 1.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($3.95 Book/Sh · -29.3% ROE) -$90M ($8.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CLYM +88.53 pp
CLYM: +47.71% · SGMO: -40.82%
3M Horizon CLYM +173.59 pp
CLYM: +104.86% · SGMO: -68.73%
6M Horizon CLYM +478.64 pp
CLYM: +418.18% · SGMO: -60.46%
1Y Horizon CLYM +478.64 pp
CLYM: +418.18% · SGMO: -60.46%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs SGMO. Trailing 12-month operating profitability (CLYM 0.0% vs SGMO -175.5%) and valuation multiples (CLYM N/M vs SGMO 0.4x Forward P/E) are benchmarked directly in Pillar 4 below.

CLYM ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-29.3% · N/M
SGMO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$40M
Gross MarginN/A
Op. Margin-175.5%
ROE / Fwd P/E-2891.8% · 0.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CLYM UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CLYM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGMO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 144.2%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SGMO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CLYM Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $638.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SGMO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $55.9M market capitalization and -175.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CLYM vs SGMO Key Questions & Quantitative Answers

As of Nov 16, 2026, Climb Bio, Inc. (CLYM) captures the overall head-to-head institutional edge over Sangamo Therapeutics, Inc. (SGMO) on higher Unified Composite conviction (41.9/100 SELL vs. 52.0/100 HOLD) after splitting the core matrix 5–4 (led by Profitability & Quality), while SGMO wins 4–1 across the 6-pillar growth and valuation breakdown. CLYM trades at $9.99 (N/M Forward P/E, 0.0% operating margin) versus SGMO at $0.18 (0.4x Forward P/E, -175.5% operating margin). Composite vs. Pillar Nuance: While SGMO currently prints a higher short-term Unified Composite Score (52.0/100 HOLD vs. CLYM 41.9/100 SELL), CLYM captures the overall institutional head-to-head verdict (5–4 matrix metrics and 1–4 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -175.5% operating margin) and revenue trajectory (+0.0% vs. +88.4% YoY). Technical & Structure Timing Caution: CLYM trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.5); meanwhile SGMO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGMO leads the Growth & Scale pillar: CLYM posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with SGMO at +88.4% YoY revenue growth and +0.0% YoY earnings growth on $40M TTM revenue (N/A gross margin, -175.5% operating margin). On trailing 12-month operating scale, CLYM generates N/A in USD-normalized revenue versus $40M for SGMO. In operating R&D and SG&A reinvestment, CLYM deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMO.

SGMO screens cheaper on headline valuation multiples. CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SGMO trades at 0.4x Forward P/E, 0.4x Trailing P/E, N/M PEG, and 1.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CLYM (-29.3% ROE) versus SGMO (-2891.8% ROE) capital efficiency.

In options market volatility and institutional positioning, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.51β · 114% Vol realized risk). By comparison, SGMO carries 144.2% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.49β · 206% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.